The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry.
Isonicotinic acid hydrazide (isoniazid) was evaluated in five patients as a treatment for the control of severe cerebellar action tremor occurring in multiple sclerosis. Oral doses of isoniazid BPC were increased every 2 weeks from 300 mg to 1200 mg daily over an 8 week period. Four patients reported considerable symptomatic benefit at doses ranging from 600 mg to 900 mg daily. Polarised light goniometry demonstrated a two to three-fold reduction of tremor in these patients when standard methods of clinical assessment showed only marginal improvement.
D000328:Adult; D001921:Brain / Q000378:metabolism; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D008027:Light; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications*; D014202:Tremor / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D005680:gamma-Aminobutyric Acid; D007538:Isoniazid